Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ACTIVE NOT RECRUITING
NCT06571591
PHASE3

Efficacy and Safety of Pioglitazone Combination Therapy in Type 2 Diabetes Patients on a Background of Empagliflozin With Metformin

Sponsor: Celltrion

View on ClinicalTrials.gov

Summary

Phase 3 study to assess the Efficacy and Safety of CT-L03-301 in Type 2 Diabetes Patients with Insufficient Glycemic Control with Metformin and Empagliflozin Combination Therapy.

Official title: A Multicentre, Randomized, Double-blind, Placebo-controlled, Phase III Study to Evaluate the Efficacy and Safety of Pioglitazone Co-administration in Patients With Type II Diabetes With Insufficient Glycemic Control With Metformin and Empagliflozin Combination Therapy

Key Details

Gender

All

Age Range

19 Years - Any

Study Type

INTERVENTIONAL

Enrollment

582

Start Date

2024-08-27

Completion Date

2026-05

Last Updated

2025-11-19

Healthy Volunteers

No

Conditions

Interventions

DRUG

CT-L03 Group 1

tablets, QD, oral administration

DRUG

CT-L03 Group 2

tablets, QD, oral administration

DRUG

Placebo

tablets, QD, oral administration

DRUG

Empagliflozin

tablet, QD, oral administration

DRUG

Metformin

tablets, oral administration

Locations (1)

Celltrion

Incheon, South Korea